|
Integritas Communications |
Share:
|
OverviewCOMMITTED TO THE DESIGN, DEVELOPMENT, AND DELIVERY OF INNOVATIVE AND CREATIVE EVIDENCE-BASED EDUCATION PROGRAMS |
An Expert Panel on Severe Asthma: From the Epithelium to Better Patient Outcomes
Severe asthma has been clearly tied to significant medical, psychological, social, and economic risks and burdens for affected patients and their families. Despite the clear need for comprehensive and intensive management, substantial gaps in patient care persist. This live Expert Roundtable"with 3 internationally recognized asthma experts who have extensive experience in clinical research,...
|
|
Answering The Call in Nonadvanced Systemic Mastocytosis
Target Audience
The design of this activity addresses the needs of clinical immunologists/allergists, dermatologists, gastroenterologists, hematologists, and other specialist clinicians who diagnose or manage nonadvanced systemic mastocytosis (SM).
Program Overview
Nonadvanced SM is a challenging disorder to diagnose and manage due to the heterogeneity of symptoms, anaphylactic triggers, an...
|
|
Can You Compete in Early Cancer Detection
This activity is an informative and engaging presentation about blood-based multi-cancer early detection MCED screening in the primary care setting. Drs. Massart, Vega, and Whittington will provide key data related to current gaps in cancer surveillance, the science and data behind MCEDs, and information on how to implement MCED screening into practice.
|
|
Can You Compete? Best Practices for Nonadvanced Systemic Mastocytosis
Don’t miss this Medical Jeopardy activity, designed to provide an informative, unique, and engaging educational approach to learning about nonadvanced systemic mastocytosis (SM)! Learners will watch a modified “Jeopardy” game, and each team will be led by our expert faculty contestants, with the didactic content presented as an explanation of the correct answer to each question. Topics cov...
|
|
Clearing a Path in Chronic Rhinosinusitis With Nasal Polyps: Closing Gaps in Diagnosis and Treatment
As many as half of patients with CRSwNP suffer from uncontrolled symptoms on a daily basis, all of which have a negative impact on both physical and mental health. Effective biological and surgical therapies for CRSwNP are becoming increasingly available and best practices for their use as well as placement within management algorithms are constantly evolving. Clearing a Path in Chronic Rhinosin...
|
|
First Steps Toward Early Diagnosis of MCI or AD
Early diagnosis of mild cognitive impairment (MCI) is critical, as many patients with MCI due to Alzheimer’s disease (AD) will eventually progress to dementia due to AD. It is imperative that diagnosis begins with patient and caregiver interviews when memory or cognitive function changes are noticed, and progress to cognitive testing and blood work to rule out other causes. Drs Charles Vega an...
|
|
Highlights of the 2023 EULAR Guideline Updates in SLE- What you need to know!
This educational program will review the latest updates to the European Alliance of Associations for Rheumatology (EULAR) guidelines for the treatment of SLE and lupus nephritis (LN). Dr. Eric Morand highlights the most important changes to the guidelines and gives key insights into actionable changes that impact individualized patient care.
|
|
Improving Alzheimer’s Disease Management: Updates on Patient Diagnosis and Treatment
The face of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) diagnosis and management is rapidly changing. A growing understanding of AD pathophysiology has shaped research of targeted therapies and helped clinicians better understand the causes of the disease and the utility of biomarkers. Though cognitive testing is still a critical component of diagnosis, it no longer stands alo...
|
|
PrEP’ing in the 2020s: Empowering PCPs to Prevent HIV
This activity is designed to empower and educate participants to offer preexposure prophylaxis (PrEP) for HIV prevention in the primary care setting. Participants will learn how to identify patients at high risk for acquiring HIV, and how to have non-biased conversations about sexual health. Through a patient-centered lens, the activity will cover implementation of PrEP services, including how t...
|
|
Putting Together Clues in HIV, CVD, T2D, and CKD
As people with HIV live longer, they can develop common comorbidities affecting aging patients, such as type 2 diabetes (T2D), cardiovascular disease (CVD), and chronic kidney disease (CKD). Further, weight gain may be seen in some patients, though the role of antiretroviral therapy (ART) is still under investigation. Clinicians should become familiar with treatment guidelines, drug-drug interac...
|
|
Raising the Bar in ATTR Amyloidosis A Training Set on Diagnosis and Treatment
There is considerable heterogeneity in the clinical manifestations of ATTR amyloidosis, which are often dependent on both genetic and environmental factors. Once a fatal diagnosis with no effective therapies available, research in ATTR amyloidosis is rapidly evolving and new pharmacotherapies that demonstrate improved quality of life and life expectancy for patients have been developed. Despite ...
|
|
Tackling Chronic Inflammatory Airway Diseases A Unified Picture of Disease Processes and Targeted Management
Chronic inflammatory diseases of the upper and lower airways, including allergic rhinitis, CRSwNP, and asthma, have been tied to significant risks and burdens for affected patients. Although biologic therapies that target overactive cytokine signaling are available, newer therapies are emerging, with targets upstream in the pathogenic cascade to improve efficacy across both T2-high and T2-low pr...
|
|
Top 10 Questions on Biomarkers in Early Alzheimer’s Disease: Improving Diagnosis and Use of Targeted Therapies
The past several years have seen numerous advances in Alzheimer’s disease (AD) diagnosis and management. Most recently, approval of antiamyloid monoclonal antibodies has revolutionized AD management and has required that patients have amyloid burden verified prior to initiating treatment. Biomarkers, whether obtained from cerebrospinal fluid (CSF) or positron emission tomography (PET) scans, a...
|
|